Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (491-500 of 1,211) with videos related to

Pageof 122
Sort By:
European Journal of Heart Failure|October 30, 2015
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristicsHenry Krum, John J V McMurray, William T Abraham, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA|September 3, 2019
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJames L Januzzi, Margaret F Prescott, Javed Butler, et al.
Circulation. Heart Failure|September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyNaoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology|April 27, 2022
Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the CommunityPeder L Myhre, Brian Claggett, Bing Yu, et al.
European Heart Journal|March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradoxJawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
Pageof 122

Showing results (491-500 of 1,211) with videos related to

Sort By:
Pageof 122
European Journal of Heart Failure|October 30, 2015
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristicsHenry Krum, John J V McMurray, William T Abraham, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
JAMA|September 3, 2019
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJames L Januzzi, Margaret F Prescott, Javed Butler, et al.
Circulation. Heart Failure|September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyNaoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)|December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection FractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology|April 27, 2022
Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the CommunityPeder L Myhre, Brian Claggett, Bing Yu, et al.
European Heart Journal|March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradoxJawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
Pageof 122